Although the impact of the E167K variant is relatively modest when compared to the PNPLA3 I148M variant, individuals harboring both the I148M and E167K variants exhibit a synergistic or additive effect, resulting in a twofold or cumulative risk of developing NAFLD [101]. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.